4.7 mRNA Vaccines, Public Health, and Safety Concerns

4.7.1 Reference to the Original NCI Report

The original NCI report titled Inquiry into the Appropriateness and Efficacy of the COVID-19 Response in Canada (November 28, 2023) examined vaccine safety as a critical element of its findings. The testimonies of Dr. Byram Bridle, Dr. Paul Thomas, and Dr. Jessica Rose during the NCI Vancouver Hearings expand on these concerns, with a focus on mRNA vaccine technology, its safety, and broader public health implications.

Introduction

The development and roll-out of mRNA vaccines during the COVID-19 event marked a significant milestone in vaccine technology. However, the rapid adoption of this new platform also introduced a range of safety, regulatory, and public health challenges. The Vancouver NCI hearings provided a platform for expert witnesses to critically evaluate the risks associated with mRNA vaccines, focusing on their safety, efficacy, and the broader implications for public health. Their testimonies highlighted the need for a thorough reassessment of the oversight and implementation of mRNA vaccine programs in Canada.

Witnesses, including Dr. Byram Bridle, Dr. Paul Thomas, and Dr. Jessica Rose, raised critical concerns about the safety of mRNA vaccines, particularly for vulnerable populations such as children, pregnant women, and individuals with pre-existing health conditions. Central themes of their testimonies included inadequate safety testing, regulatory failures, and alarming trends in adverse event reporting. They also emphasized systemic issues related to the transparency and accountability of public health institutions, pointing to significant gaps in how mRNA vaccines are assessed and monitored.

A major area of focus was the safety of mRNA vaccine components, such as lipid nanoparticles (LNPs) and aluminum adjuvants, which are integral to the vaccine's delivery and efficacy. Witnesses warned about the potential bio-distribution and persistence of these components in the body, raising concerns about their impact on vital organs, including the brain, liver, and reproductive system. Compounding these concerns were findings of DNA contamination, in vaccine vials, which included SV40 fragments, known to promote cancer, that exceeded established safety thresholds.

The testimonies also brought attention to troubling trends in adverse event reporting. Data from the Vaccine Adverse Event Reporting System (VAERS) revealed a dramatic surge in reported adverse events following the introduction of mRNA vaccines. Witnesses pointed to inconsistencies in safety monitoring and quality control, which undermined confidence in the safety of these vaccines. Regulatory agencies’ reliance on manufacturer supplied data, without adequate external oversight, was identified as a critical flaw in the system.

The hearings underscored the need for a more cautious and evidence-based approach to mRNA vaccine policies, particularly for children and pregnant women. Witnesses advocated for independent oversight, enhanced safety testing, and improved regulatory accountability, plus an outright moratorium on their use in all populations. They also highlighted the broader public health implications of eroding trust in vaccination programs, which could have lasting consequences for future public health initiatives.

This section synthesizes the testimonies presented during the NCI Vancouver Hearings, offering a comprehensive examination of the risks associated with mRNA vaccines and the systemic challenges in their oversight. By addressing these issues, the findings presented in this section aim to support meaningful reforms that prioritize public safety, rebuild trust, and ensure the transparency and accountability of vaccination programs in Canada.

Discussion of Witness Testimonies

Dr. Byram Bridle

Overview of Testimony

Dr Bridle is a widely published expert in the fields of immunology, Virology and Vaccinology and has conducted extensive grant-funded research into vaccines, including for COVID-19. His review of the preclinical and clinical research data concerning the mRNA vaccines developed for COVID-19 led him to very serious concerns about the validity of the data on effectiveness and safety. As a result of expressing those concerns, he has suffered significant damage to his career and professional reputation. His concerns are summarized below.

Pfizer COVID-19 Vaccine structure safety concerns

The vaccine is composed of Lipid Nanoparticles (LNPs) within which viral mRNA coding for the viral spike protein (S protein) is enclosed. This technology enables insertion of the mRNA into mammalian cells which then coerces the cell’s own protein synthesis mechanisms to produce spike protein which is subsequently expressed on the cell surface.

Polyethylene Glycol (PEG) is also included in the vaccine to enhance systemic bio-distribution.

LNPs are toxic and may cause anaphylaxis, especially following repeated exposure, as occurs with repeated vaccine boosters.

The spike protein produced following vaccination is itself a noxious substance especially when forming complexes with S protein antibodies and is responsible for many of the clinical features of COVID-19 infection. There is also evidence that ‘misreading’ of the vaccine mRNA may produce variant S proteins whose effects are unpredictable.

The vaccines have also been shown to contaminated with viral DNA though the possible consequences of this have not been adequately researched.

The most recent iteration of the vaccine technology has added an enzyme which promotes replication of the delivered mRNA and this has now entered clinical use in Japan.

Bio-distribution Concerns

Although the public were informed that “the vaccine stays at the injection site” the initial rodent studies done by Pfizer show that this is not the case. Only approximately 20% of the vaccine components stay at the injection site. The remainder is widely distributed in many tissues and organs, including the kidneys and adrenals, lungs and skin. The LNPs readily pass the blood-brain barrier and spike protein (S protein) has been demonstrated in the brain.

A further concern is that the data from the initial studies presented to the regulatory bodies in Japan and the Food and Drug Administration in the USA were manipulated in a way that minimized evidence of widespread distribution of the vaccine components. This manipulation included cropping of images of test animals to exclude evidence of vaccine components concentrated away from the injection site.

Many peer-reviewed studies are now available confirming the wide distribution of the vaccine components in human tissues and organs.

Bio-persistence Concerns

The FDA said that studies in animals showed the vaccine ingredients returned to normal levels in the body after 9 days. But the actual data tells a different story. While the levels did go down, they hadn’t fully returned to normal by day 9. Also, the data combined results from both male and female animals. When researchers looked at males and females separately, they found something important: in male animals, the vaccine ingredients were decreasing (though still not quite back to normal), but in female animals, the levels were still going up in almost every organ all the way to the end of the study.

Peer-reviewed studies are now available which show persistence of S protein in widespread tissues for many months and sometimes at alarmingly high concentrations.

Clinical Data in Humans

Pfizer’s own initial published statements say that the vaccine is indicated to prevent COVID-19 infection. This has subsequently been altered to state that “The vaccine may contribute to protection against COVID-19.” Pfizer has not made any claims that the vaccine could reduce the severity of infections, though public health authorities have publicly made that claim.

The first clinical trials were conducted in young healthy volunteers and did show a “small but statistically significant protective effect against infection.” This group however is at minimal risk from COVID-19 and the trial results do not necessarily imply effectiveness in a roll-out to the general population.

Pfizer itself has acknowledged a higher reporting of 7.3% fatal outcomes in vaccinated frail, elderly patients compared to the general population.

Data from the Ministry of Health in British Columbia comparing patients given the COVID-19 vaccine versus historical data for the influenza vaccine show that adverse events were 11 times higher following COVID-19 vaccination, severe adverse events were 16 times higher, hospitalizations were 14 times higher and deaths were 28 times higher per dose.

Concerns About Pregnant and Lactating Women

In response to a question tabled in the Canadian Parliament by the Member for Yorkton-Melville asking “What is Health Canada’s scientific basis for claiming safety of the vaccine in pregnant and lactating women?”, Health Canada eventually responded that it “had not approved any safety claims with respect to pregnant and lactating women.” Pfizer’s own product monograph also states clearly that “safety has not been established in pregnant and lactating women.”

Despite this, Federal and Provincial officials, including the Ontario Minister of Health, have continued to claim otherwise and encouraged vaccine usage in this patient group.

Before authorization was granted for use of the COVID-19 vaccine in pregnant and lactating women, a number of such patients were treated (some did not know they were pregnant and some were treated erroneously). A study of this group has shown that 25% of the mothers and 25% of children reported side-effects from the vaccine, and 50% of the reported side effects were “severe.”

Data from the BC Ministry of Health show that serious side-effects in women following COVID-19 vaccination were 18 times higher than those following influenza vaccinations.

Concerns About “Shedding”

Following vaccination, viral mRNA or mRNA fragments have been shown to occur in breast milk, faeces and urine. There is increasing evidence that shedding may also occur from skin and saliva and possibly respiratory droplets. The clinical significance of this is unclear and more research needs to done urgently to identify any harms. There is also concern that the new technology of self replicating mRNA vaccines may lead to increased levels and persistence of shedding.

Dr Bridle’s Conclusions

• mRNA injections should be completely suspended in the light of the available data.

• Incorrect information and advice about the COVID-19 vaccines produced by health authorities means that true informed consent is not possible.

• Given the experience with COVID-19 injection policies, it is likely that the data supporting the authorization of a wide range of other vaccines should be carefully reviewed.

The health consequences of mRNA vaccines may be chronic and increase over time and this will require diligent monitoring.

Key Points from Testimony:

• Bio-distribution Issues: Contrary to claims that vaccine components remain localized at the injection site, Pfizer’s preclinical studies revealed that only 20% stayed at the injection site, while 80% distributed across various organs, including the brain, liver, and reproductive organs.

• Bio-persistence: Vaccine components persisted far longer in the body than the nine day baseline initially reported. Differences in male and female metabolism further complicate the understanding of vaccine safety.

• Adverse Events Data: Data from British Columbia indicated that adverse event rates following COVID-19 vaccination were up to 28 times higher than those for influenza vaccines.

• Safety for Pregnant Women: Despite limited safety data for pregnant and lactating women, mRNA vaccines were widely recommended for this group, leading to reports of elevated adverse outcomes.

Dr. Paul Thomas

Overview of Testimony

Dr. Paul Thomas, a Board Certified Paediatrician and Addiction Medicine Specialist, testified about the health outcomes associated with vaccination practices. His “vaccine friendly" approach allowed parents to adopt modified schedules, and his research examined differences in health outcomes between vaccinated and unvaccinated children. He later came to the collusion that he could not recommend any vaccines for children.

Key Points from Testimony:

• Health Outcomes Study: Dr. Thomas’s peer reviewed research found lower rates of asthma, ADHD, and behavioural issues in unvaccinated children compared to vaccinated counterparts.

• Aluminum Adjuvants: He criticized the presence of aluminum in vaccines, highlighting that doses often exceeded FDA safety limits for infants.

• Correlation with SIDS: Dr. Thomas referenced peer-reviewed studies indicating that 97% of Sudden Infant Death Syndrome (SIDS) cases occurred within 10 days of vaccination.

• Adverse Event Data: VAERS data showed an exponential increase in reported adverse events following the introduction of COVID-19 vaccines, with higher rates of hospitalizations and deaths.

Dr. Jessica Rose

Overview of Testimony

Dr. Jessica Rose, a computational biologist with expertise in vaccine adverse event analysis, presented detailed insights into systemic flaws in the reporting and oversight of mRNA vaccine safety.

Key Points from Testimony:

• DNA Contamination in Vaccine Vials: Testing revealed DNA contamination exceeding WHO standards, including the presence of SV40 fragments, a known cancer-promoting agent.

• VAERS Trends: Annual adverse event reports surged from 39,000 pre-COVID to over 750,000 in the first year of the mRNA vaccine roll-out. Deaths per 1,000,000 doses were 70 times higher for COVID-19 injections compared to influenza vaccines.

• Risks to Children: VAERS data for children aged 0-17 showed disproportionately high rates of adverse events, particularly in the 12-17 age group.

Priya Sall

Overview of Testimony

Priya Sall testified about her experience as a vaccine-injured young person, discussing the health challenges she faced after receiving COVID-19 vaccinations. Her testimony focused on the physical toll, the medical response she received, and her call for other young people to come forward with similar experiences.

Key Points

1. Pre-Vaccine Health and Disability: Sall was born prematurely at 25 weeks, weighing only two pounds. Due to her premature birth, she was diagnosed with cerebral palsy (level three) and a vision impairment.

• She used a walker for mobility outside her home but was able to walk indoors independently.

• These conditions existed prior to receiving the COVID-19 vaccine.

1. Health Complications Following Vaccination:

• Sall reported experiencing severe adverse effects following the COVID-19 vaccine, including seizures.

• Her father called emergency services after her third seizure, and she was taken to the hospital.

• While in the hospital, she underwent blood work and basic medical assessments, but she was not admitted for extended care.

• She was told she would receive an EEG to investigate potential neurological damage, but it took three months before she was able to get the necessary medical equipment for testing.

1. Call for Awareness and Advocacy:

• Sall encouraged other young people who believe they were injured by vaccines to come forward and share their stories.

• She warned parents and young individuals to be skeptical of mainstream news narratives, arguing that misinformation could have life-threatening consequences.

• She cited the case of Sean Hartman, a 16-year old who allegedly died after receiving a COVID-19 vaccine in order to play hockey, using his story as a cautionary example.

• She expressed support for legal actions against pharmaceutical companies and government agencies, hoping that lawsuits would set a precedent for accountability.

Priya Sall’s testimony highlights the challenges faced by individuals who report vaccine injuries, particularly in accessing medical care and recognition. Her case underscores concerns about medical responsiveness, long wait times for neurological assessments, and the emotional and physical toll of adverse effects. She positioned her experience within a broader call for advocacy, urging others to come forward and pushing for legal and systemic accountability.

Discussion and Analysis of Issues Raised by the Witnesses

Challenges in Ensuring Vaccine Safety

The testimonies of Dr. Byram Bridle, Dr. Paul Thomas, and Dr. Jessica Rose collectively raised significant concerns about the safety and oversight of mRNA vaccines. Dr. Bridle’s testimony on bio-distribution and bio-persistence issues challenged initial assurances about the localized nature of vaccine components, suggesting that their systemic spread could have long-term health implications. This lack of clear and transparent data about the distribution of vaccine components underscores a critical gap in regulatory oversight, particularly as it relates to vulnerable populations such as pregnant women.

Dr. Thomas reinforced these concerns by highlighting systemic weaknesses in vaccine testing and safety standards, including the use of aluminum adjuvants that exceed safety thresholds for infants. His findings also linked vaccination policies to increased risks of chronic illnesses and adverse reactions, emphasizing the need for rigorous pre-approval testing and continuous post-marketing surveillance.

Dr. Rose’s analysis of VAERS data pointed to a sharp increase in adverse event reporting following the introduction of COVID-19 vaccines. The presence of DNA contamination in vaccine vials raised additional red flags about the manufacturing and quality control processes. The testimony of all three experts underscores a failure to ensure vaccine safety through adequate testing, transparent data-sharing, and regulatory accountability.

Systemic Regulatory and Reporting Failures

Dr. Rose’s VAERS analysis revealed systemic issues in adverse event reporting and follow-up. The exponential rise in adverse event reports, moving from 39,000 annually pre-COVID to over 750,000 during the first year of mRNA vaccine roll-out, suggests a significant underestimation of vaccine related risks. Regulatory agencies’ apparent lack of urgency in responding to these signals undermines public trust and raises ethical questions about vaccine promotion without robust safety evaluations.

Both Dr. Bridle and Dr. Rose emphasized the need for independent oversight of regulatory bodies to address conflicts of interest and ensure unbiased monitoring of vaccine safety. The current reliance on manufacturers’ data without rigorous external review compromises the credibility of public health decisions, leaving gaps in accountability and transparency.

Risks to Vulnerable Populations

All three witnesses highlighted the disproportionate risks posed by mRNA vaccines to vulnerable groups, including children, pregnant women, and individuals with pre-existing health conditions. Dr. Bridle expressed alarm about the promotion of vaccines to pregnant women despite insufficient safety data, while Dr. Rose’s VAERS analysis showed elevated adverse event rates among children, particularly in the 12-17 age group.

Dr. Thomas’s testimony expanded on the risks associated with current vaccination policies, particularly for infants and young children exposed to aluminum adjuvants and other vaccine components. His findings linked vaccination schedules to an increased prevalence of conditions like asthma, ADHD, and behavioural issues, calling for a more cautious approach to pediatric vaccination.

The recurring theme across all testimonies is the failure of public health authorities to adopt a precautionary approach, instead prioritizing mass vaccination strategies without fully understanding the risks to vulnerable populations.

Erosion of Public Trust in Health Systems

The testimonies underscored the erosion of public trust in health institutions, fuelled by a lack of transparency, inadequate public consultation, and insufficient accountability. Dr. Bridle’s revelations about bio-distribution and bio-persistence contradicted public health messaging, raising questions about the credibility of regulatory agencies. Dr. Rose’s identification of contamination issues further undermined confidence in vaccine manufacturing processes.

Public trust is foundational to effective public health strategies, and the failure to address safety concerns or respond to adverse event signals has significant implications for future vaccination campaigns. Witnesses consistently called for greater transparency, independent monitoring, and open communication to rebuild trust and ensure the safety of future public health initiatives.

Conclusion

The testimonies of Dr. Bridle, Dr. Thomas, and Dr. Rose underscore profound concerns about the safety of mRNA vaccines, the integrity of regulatory systems, and the ethics of public health practices. Their findings highlight significant gaps in oversight, transparency, and accountability, necessitating immediate action to rebuild public trust in Canada’s healthcare system.

Recommendations

1. Suspend mRNA Vaccine Roll-out:

• Implement an immediate moratorium on mRNA vaccines until independent safety verification is conducted.

2. Enhance Regulatory Oversight:

• Establish independent bodies to monitor vaccine safety and adverse events.

• Enforce stricter production standards to minimize contamination risks.

3. Improve Data Collection and Transparency:

• Mandate public reporting of all adverse events and ensure VAERS data is regularly updated and accessible.

• Conduct independent audits of vaccine trial data.

• Mandate publication of vaccine trials data.

4. Reevaluate Vaccine Policies:

• Promote informed consent by providing clear, accurate information on vaccine risks and benefits.

• Develop alternative public health strategies to reduce reliance on mass vaccination.

5. Support Research and Accountability:

• Fund long-term studies on the effects of mRNA injections.

• Hold manufacturers and regulatory agencies accountable for safety violations and data omissions.

By implementing these recommendations, Canada can prioritize public safety and restore confidence in its healthcare systems.